SANGAMO THERAPEUTI revenue breakdown overview

SANGAMO THERAPEUTI revenue for the last year amounted to 52.49 M CHF, the most of which — 52.49 M CHF — came from its highest performing source at the moment, Epigenetic, the year earlier bringing 148.38 M CHF. The greatest contribution to the revenue figure was made by United States — last year it brought SANGAMO THERAPEUTI 52.49 M CHF, and the year before that — 148.38 M CHF.